BioCryst Pharma (BCRX) Reports Q4 Loss of $0.40/sh
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.07 +3.81%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
JAGX, CLIR, ZTO, More
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
JAGX, CLIR, ZTO, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.40), versus ($0.34) reported last year. Revenue for the quarter came in at $47.2 million, versus $4 million reported last year.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- Accuray (ARAY) Tops Q4 EPS by 1c
- Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
